Patients with cardiac amyloidosis (CA) commonly develop iron deficiency (ID) regardless of the subtype. In CA patients, there appears to be a greater likelihood of having ID if diagnosed with ATTR, if diabetic, and/or treated with aspirin. In CA cases, the advantage of intravenous iron therapy, for ID, on morbidity and mortality requires further exploration.

• This analysis was conducted to report the prevalence, clinical result (all-cause mortality), and determinants of ID among the three main subtypes of CA: light chain (AL), hereditary transthyretin (ATTRv), and wild-type transthyretin (ATTRwt).

• In this study of 816 CA patients, ID affected 49% of patients, 45% with AL, 58% with ATTRv, and 48% with ATTRwt.

• The identified independent ID determinants included ATTR status, diabetes, aspirin treatment, haemoglobin levels, and altered global longitudinal strain.

• No difference in all-cause mortality was observed considering ID status.